Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer. [PDF]
BiomoleculesMammadova A +4 more
europepmc +1 more source
Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis. [PDF]
J Pharm Policy PractElazzazy S +5 more
europepmc +1 more source
CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer. [PDF]
Breast Cancer ResYan Y +13 more
europepmc +1 more source
Aberrant CDK4/6-driven cell-cycle reentry drives neuronal loss and defines a therapeutic target in C9orf72 ALS/FTD. [PDF]
iScienceLian L +5 more
europepmc +1 more source
BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p. [PDF]
Clin Cancer ResLiu R +9 more
europepmc +1 more source
CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. [PDF]
Target OncolPark D +4 more
europepmc +1 more source
Age-stratified toxicity patterns of CDK4/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database. [PDF]
BreastKöylü B +10 more
europepmc +1 more source
Correction: CDK4/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity. [PDF]
Cancer Cell IntCai X +5 more
europepmc +1 more source